Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633908 | 0.92 | DAO (0.49) | FFAR1FFAR4PTGDR2DAOIDO1 | |
| SCHEMBL12835379 | 0.92 | DAO (0.49) | FFAR1FFAR4PTGDR2DAOIDO1 | |
| SCHEMBL2393327 | 0.87 | POLB (0.54) | FFAR1FFAR4PTGDR2POLB | |
| SCHEMBL30151142 | 0.87 | IDO1 (0.49) | FFAR1FFAR4PTGDR2IDO1 | |
| SCHEMBL15094094 | 0.83 | POLQ (0.51) | FFAR1FFAR4PTGDR2DAO | |
| SCHEMBL30530542 | 0.83 | IDO1 (0.51) | FFAR1PTGDR2DAOIDO1 | |
| SCHEMBL512428 | 0.83 | IDO1 (0.51) | FFAR1PTGDR2DAOIDO1 | |
| SCHEMBL3685960 | 0.82 | PTGDR2 (0.49) | FFAR1FFAR4PTGDR2 | |
| SCHEMBL4007916 | 0.82 | FFAR1 (0.58) | FFAR1FFAR4PTGDR2DAO | |
| SCHEMBL29009780 | 0.81 | MGLL (0.47) | FFAR1FFAR4PTGDR2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-23 | — | — | US | disclosed |
| CN-101568542-B | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD | 2013-03-27 | — | — | CN | disclosed |
| US-8188082-B2 | 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2125823-B1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| CN-102076694-A | 5, 6, 7, 8-tetrahydro-imidazo[1, 5-a]pyrazine compounds | ACTELION PHARMACEUTICALS LTD | 2011-05-25 | — | — | CN | disclosed |
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| EP-2307417-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100029617-A1 | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029617-A1 | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2009156951-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-30 | — | — | WO | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| CN-101568542-A | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-28 | — | — | CN | disclosed |
| CN-101511833-A | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2059520-A1 | 1,4,5,6, 7,8-HEXAHYDRO-I^1S-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008026149-A1 | 1,4,5,6, 7,8-HEXAHYDRO-I^1S-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008026149-A1 | 1,4,5,6, 7,8-HEXAHYDRO-I^1S-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | HCRTR1, HCRTR2, NPY5R | FFAR1 204/4885FFAR4 295/4885PTGDR2 591/4885 |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | FFAR1 192/4885FFAR4 191/4885PTGDR2 611/4885 |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | FFAR1 3119/4885FFAR4 3664/4885PTGDR2 365/4885 |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | FFAR1 3332/4885FFAR4 3718/4885PTGDR2 558/4885 |
| US-20100029617-A1 | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY5R | FFAR1 137/4885FFAR4 202/4885PTGDR2 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.